International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]
.. IB Australian Bioscience Fund I outperforms ASX200AI by 72% Delivers ~30% annual IRR* Melbourne, Australia 8 April 2013: A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the […]
(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6. Nexus6’s SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage […]
BioScience Managers Pty Ltd (formerly Octa Phillip Bioscience Managers) today fully endorsed the move by Bioxyne Ltd (ASX:BXN) to acquire Asia Pacific medical device company, Vitality Devices Pty Ltd. Following Bioxyne’s existing product HI-164OV failing to reach clinical trial endpoints last year, BioScience Managers, a 20+% shareholder in BXN, has been at the forefront of […]
Top Decile[1] Fund Manager announces first close on second fund First closing at A$55m supported by Australian institutions IOOF provides $45m cornerstone Focused on clinical stage healthcare and life sciences firms First investment $3m into ASX Listed Avita (ASX.AVH) Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), today announced a successful first close on its […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2012-11-08 17:39:442018-01-06 17:40:11Bioscience Managers Announces First Close on New Healthcare Fund
IB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital (NZX.CLA) in conjunction with Claridge’s acquisition of SeaDragon Marine Oils. The subscription arrangement is conditional upon the satisfaction of a number of commercial conditions. The […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2012-09-11 17:40:302019-02-13 12:39:58Australian Bioscience Fund I to invest in Sea Dragon Marine Oils
Octa Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of the appointment of Dr William (Bill) Hunter to its board. William Hunter co-founded Angiotech Pharmaceuticals in 1992 while still being a medical student at university. […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2012-07-16 17:29:402018-01-06 17:30:47Angiotech Founder Joins Union Medtech & Bioscience Managers’ Global Team
New look Octa Phillip Bioscience Managers (Bioscience Managers – formerly IB Managers) is looking to create an all-star team with the addition of Starmine top rated analyst Dr Graeme Wald as it progresses towards a first close on its second fund. With its first fund’s performance confirmed in the top decile of global (2008 ex-US) […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2012-05-11 17:31:212018-01-06 17:31:44Leading Fund Manager Snares Star Analyst
Bioscience Managers Supports Bioxyne Decision on Transaction
/in BioSciences ManagersInternational life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]
Super Funds Urged To Consider Healthcare Sector For Exceptional Returns
/in BioSciences Managers.. IB Australian Bioscience Fund I outperforms ASX200AI by 72% Delivers ~30% annual IRR* Melbourne, Australia 8 April 2013: A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the […]
BioScience Managers Expands Asia Pac Presence – Invests $3M in NZ Patient Monitoring Company
/in BioSciences Managers(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6. Nexus6’s SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage […]
BioScience Managers Backs Bioxyne Move
/in BioSciences Managers, Portfolio CompaniesBioScience Managers Pty Ltd (formerly Octa Phillip Bioscience Managers) today fully endorsed the move by Bioxyne Ltd (ASX:BXN) to acquire Asia Pacific medical device company, Vitality Devices Pty Ltd. Following Bioxyne’s existing product HI-164OV failing to reach clinical trial endpoints last year, BioScience Managers, a 20+% shareholder in BXN, has been at the forefront of […]
Bioscience Managers Announces First Close on New Healthcare Fund
/in BioSciences ManagersTop Decile[1] Fund Manager announces first close on second fund First closing at A$55m supported by Australian institutions IOOF provides $45m cornerstone Focused on clinical stage healthcare and life sciences firms First investment $3m into ASX Listed Avita (ASX.AVH) Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), today announced a successful first close on its […]
Australian Bioscience Fund I to invest in Sea Dragon Marine Oils
/in BioSciences Managers, SeaDragonIB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital (NZX.CLA) in conjunction with Claridge’s acquisition of SeaDragon Marine Oils. The subscription arrangement is conditional upon the satisfaction of a number of commercial conditions. The […]
Angiotech Founder Joins Union Medtech & Bioscience Managers’ Global Team
/in BioSciences ManagersOcta Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of the appointment of Dr William (Bill) Hunter to its board. William Hunter co-founded Angiotech Pharmaceuticals in 1992 while still being a medical student at university. […]
Leading Fund Manager Snares Star Analyst
/in BioSciences ManagersNew look Octa Phillip Bioscience Managers (Bioscience Managers – formerly IB Managers) is looking to create an all-star team with the addition of Starmine top rated analyst Dr Graeme Wald as it progresses towards a first close on its second fund. With its first fund’s performance confirmed in the top decile of global (2008 ex-US) […]